Remedy

Abstract

It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.

1 . A remedy for treating diseases comprising particles by which phagocytic activity of macrophages is facilitated wherein
 the particles have diameters of 1 to 6 μm, being made of PLGA poly(lactic acid/glycolic acid) copolymer) with a molecular weight of 5,000 to 75,000, a monomer ratio of lactic acid/glycolic acid being 50:50 to 75:25;   the particles contain at least one member selected from the group consisting of PVA (polyvinyl alcohol), PEG (polyethylene glycol), sugar, protein, peptide phospholipid and cholesterol   the particles contain one or both of lipopolysaccharide and a medicament, the medicament exterminates to vanish all or a part of the pathogens present in the macrophages.   
     
     
         2 . A remedy wherein the remedy comprises lipopolysaccharide, facilitates phagocytic activity of macrophages and leads cell death to pathogen-retaining macrophages. 
     
     
         3 . A remedy for cancer, wherein the remedy comprises lipopolysaccharide, facilitates phagocytic activity of macrophages, acts upon the macrophages in a dysfunctional state, and has cytotoxic effect on cancer cells. 
     
     
         4 . The remedy according to  claim 1 , for mycobacteriosis, AIDS, chlamydiosis or toxoplasmosis. 
     
     
         5 . The remedy according to  claim 2 , for Crohn's disease, rheumatoid, cancer or immunodeficiency syndrome. 
     
     
         6 . The remedy according to  claim 1 , wherein said macrophages are resident in mucosal tissue. 
     
     
         7 . The remedy according to  claim 1 , wherein said macrophages are resident in any of peritoneal cavity, greater omentum, milky spot, pulmonary alveolus, pulmonary stroma, liver, portal vein area, spleen, bone marrow, thymus, digestive tract, palatine tonsil, adrenal gland, pituitary, thyroid stroma, Langerhans islet, parathyroid gland, pineal gland, testis, ovary, oviduct, uterus, placenta, skin, meningis, brain substance and choroid plexus, or the above macrophages are microglia, precursor cells of microglia, glia cells, precursor cells of glia cells, precursor cells of the above resident macrophages, analogous cells of the above resident macrophages, or precursor cells of the above resident macrophage analogous cells. 
     
     
         8 . The remedy according to  claim 1 , for tuberculosis. 
     
     
         9 . The remedy according to  claim 8 , wherein the medicament is rifampicin. 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . The remedy according to  claim 1 , wherein the phagocytic activity of the macrophages is facilitated by the particle being phagocytosed. 
     
     
         15 . The remedy according to  claim 1 , comprising PLGA where a molecular weight is 5,000 to 20,000 and being for tuberculosis. 
     
     
         16 . The remedy according to  claim 15 , fabricated by membrane emulsification method. 
     
     
         17 . The remedy according to  claim 2  comprising lipopolysaccharide of  Pantoea agglomerans  and being for AIDS. 
     
     
         18 . The remedy according to  claim 3 , comprising lipopolysaccharide of  Pantoea agglomerans  and having cytotoxic effect on lung cancer cells. 
     
     
         19 . A method of treating AIDS comprising;
 facilitating a phagocytic activity of macrophages by a lipopolysaccharide to activate the macrophages;   inducing a change of a membrane structure in the macrophages;   inducing a membrane-bound tumor necrosis factor (TNF) in the macrophages, and inducing cell death of the macrophages.   
     
     
         20 . The method according to  claim 19 , wherein the lipopolysaccharide is derived from  Pantoea agglomerans.    
     
     
         21 . The method according to  claim 19 , wherein the macrophages are MOLT-4 cells infected with HIV. 
     
     
         22 . A method for treating lung cancer comprising
 facilitating a phagocytic activity of macrophages by a lipopolysaccharide;   inducing the macrophages into dysfunctional state to make the macrophages cytotoxic, and   contacting the macrophages with lung cancer cells.   
     
     
         23 . The method according to  claim 22 , wherein the macrophages are alveolar macrophages. 
     
     
         24 . The method according to  claim 23 , wherein the alveolar macrophages are NR8383 cells. 
     
     
         25 . The method according to  claim 22 , wherein the lung cancer cells are Sato lung cancer cells. 
     
     
         26 . The method according to  claim 22 , wherein the lipopolysaccharide is derived from  Pantoea agglomerans.    
     
     
         27 . A method for treating tuberculosis comprising:
 preparing the remedy of  claim 9 ;   contacting the remedy to macrophages hosted tuberculosis germs, and   making the macrophages phagocytose the remedy.   
     
     
         28 . A method for improving treatment efficiency of tuberculosis comprising:
 preparing the remedy of  claim 9 ;   contacting the remedy to macrophages hosted tuberculosis germs, and   making the macrophages phagocytose the remedy.